|
|
News Breaks | | | | March 7, 2013 | | 07:08 EDT |  | SRPT | Sarepta reports Q4 EPS ($2.36), may not compare to consensus (29c)
Reports Q4 revenue $7.3M, consensus $6.71M. Says increase in the net loss for both the fourth quarter and the year was primarily due to the change in the valuation of outstanding warrants to purchase common stock. In connection with prior equity financings, Sarepta issued warrants that are classified as current liabilities and are adjusted to fair value on a quarterly basis with the change in fair value being included in net loss. The amount included in net loss is a non-cash item as Sarepta is not required to expend any cash to settle the warrant liability. The warrant liability is primarily affected by changes in Sarepta's stock price during each financial reporting period which causes the warrant liability to fluctuate as the market price of Sarepta's stock fluctuates. In the fourth quarter of 2012, the increase in Sarepta's stock price resulted in the warrant valuation increasing which resulted in other expense of $51.8M. | |
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | SRPT | UBS to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | |
|
|
|
|
|
|
